Nanohale AG (ETR:FYB)

BRIEF

published on 10/02/2025 at 06:35, 9 months 23 days ago

Formycon Secures U.S. License for Aflibercept Biosimilar

Formycon AG U.S. Market Launch Aflibercept Biosimilar Regeneron Agreement Patent Dispute Resolution
PRESS RELEASE

published on 10/02/2025 at 06:30, 9 months 23 days ago

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026

Formycon Regeneron Valorum Biologics Aflibercept Biosimilar Patent Disputes
BRIEF

published on 09/17/2025 at 16:00, 10 months 8 days ago

Formycon AG: Updated Research and Performance Forecast

Revenue Forecast Biosimilars Formycon FYB202 FYB206
PRESS RELEASE

published on 09/17/2025 at 15:55, 10 months 8 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates rating on Formycon AG (ISIN: DE000A1EWVY8) to Buy with a target price of €48. Analyst expects revenue to rebound in H2 and Q4 due to FYB202 and FYB206 developments

First Berlin Equity Research BUY Rating Formycon AG Update Target Price
BRIEF

published on 09/17/2025 at 06:35, 10 months 8 days ago

Horus Pharma Joins Formycon's Eylea® Biosimilar Commercialization

Commercialization Biosimilar Formycon Baiama Horus Pharma
PRESS RELEASE

published on 09/17/2025 at 06:30, 10 months 8 days ago

Horus Pharma becomes additional commercialization partner for Formycon's Eylea® biosimilar FYB203 in selected European countries under the brand name Baiama®
Horus Pharma partners with Formycon for Eylea biosimilar commercialization in Europe under Baiama brand. Agreement includes upfront payments and royalties for Klinge. Aflibercept treats nAMD

Agreement Formycon Eylea Biosimilar Horus Pharma Baiama Brand
BRIEF

published on 08/13/2025 at 06:35, 11 months 12 days ago

Formycon Affirms Full-Year Outlook After Strategic Developments

Formycon AG Corporate Bond Biosimilar Market 2025 Financial Guidance FYB202 & FYB206
PRESS RELEASE

published on 08/13/2025 at 06:30, 11 months 12 days ago

Formycon confirms full-year guidance following business development in line with plan – working capital raised
Formycon AG confirms full-year guidance with successful business development. Working capital raised through oversubscribed corporate bond. Strong second half expected

Working Capital Business Development Formycon AG Corporate Bond Full-year Guidance
BRIEF

published on 08/04/2025 at 11:50, 11 months 21 days ago

Formycon AG Gains Strong Buy Rating Amid Strategic Developments

Formycon AG Bond Issue Financial Update Equity Research FYB202 Launch
PRESS RELEASE

published on 08/04/2025 at 11:45, 11 months 21 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Formycon AG analysis, maintaining BUY rating with increased target price of €49. Company aims for 2025 revenue of €55-65m and improved financial position after new corporate bond issuance

First Berlin Equity Research BUY Rating Formycon AG Target Price Corporate Bond Issuance

Published on 07/25/2026 at 00:35, 1 day 2 hours ago

Pathfinder Ventures Inc. Provides Corporate Update
Published on 07/24/2026 at 23:00, 1 day 3 hours ago

NV Gold Announces Closing of Non-Brokered Private Placement
Published on 07/24/2026 at 22:15, 1 day 4 hours ago

Gold Terra Announces Closing of First Tranche of C$10.8M LIFE Offering With Strong Participation From Strategic Shareholder David Harquail
Published on 07/24/2026 at 22:05, 1 day 4 hours ago

Findev Inc. Announces CCAA Proceedings Involving 1682 Victoria Park Avenue Inc. and Related Party Subordination Arrangement
Published on 07/24/2026 at 20:00, 1 day 6 hours ago

Unusual Machines to Announce Second Quarter 2026 Financial Results and Provide Corporate Update

View all ACCESSWIRE

Published on 07/24/2026 at 19:06, 1 day 7 hours ago

End of Stabilisation Notice
Published on 07/24/2026 at 19:04, 1 day 7 hours ago

Stabilisation Notice
Published on 07/24/2026 at 18:44, 1 day 8 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/24/2026 at 17:50, 1 day 8 hours ago

Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 07/24/2026 at 17:40, 1 day 9 hours ago

2CRSi SA: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital as of May 31, 2026.

View all EQS

Published on 07/24/2026 at 18:50, 1 day 7 hours ago

Disclosure of transactions in own shares from July 20 to July 24, 2026
Published on 07/24/2026 at 18:11, 1 day 8 hours ago

H1 2026 liquidity contract statement for TF1
Published on 07/24/2026 at 18:06, 1 day 8 hours ago

TF1 First-Half 2026 Financial Report
Published on 07/24/2026 at 18:00, 1 day 8 hours ago

TF1 H1 2026 results - Press release
Published on 07/24/2026 at 08:00, 1 day 18 hours ago

Accor signs a definitive binding agreement on the sale of its stake in Essendi

View all LES ECHOS COMFI WIRE

News